Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. - Kelly PN; Romero DL; Yang Y; Shaffer AL 3rd; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM (The Journal of experimental medicine, 2015)